Uptake of the OMERACT-OARSI hip and knee osteoarthritis core outcome set: Review of randomized controlled trials from 1997 to 2017

Toby O. Smith; Michael Mansfield; Gillian A. Hawker; David J. Hunter; Lyn M. March; Maarten Boers; Beverley J. Shea; Robin Christensen; Francis Guillemin; Caroline B. Terwee; Paula R. Williamson; Ewa M. Roos; Richard F. Loeser; Thomas J. Schnitzer; Margreet Kloppenburg; Tuhina Neogi; Christoph H. Ladel; Gurdyal Kalsi; Ulrike Kaiser; Thomas W. Buttel; Anne E. Ashford; Ali Mobasheri; Nigel K. Arden; Alan Tennant; Marc C. Hochberg; Maarten de Wit; Peter Tugwell; Philip G. Conaghan

doi:10.3899/jrheum.181066

Uptake of the OMERACT-OARSI hip and knee osteoarthritis core outcome set: Review of randomized controlled trials from 1997 to 2017

Toby O. Smith, Michael Mansfield, Gillian A. Hawker, David J. Hunter, Lyn M. March, Maarten Boers, Beverley J. Shea, Robin Christensen, Francis Guillemin, Caroline B. Terwee, Paula R. Williamson, Ewa M. Roos, Richard F. Loeser, Thomas J. Schnitzer, Margreet Kloppenburg, Tuhina Neogi, Christoph H. Ladel, Gurdyal Kalsi, Ulrike Kaiser, Thomas W. ButtelAnne E. Ashford, Ali Mobasheri, Nigel K. Arden, Alan Tennant, Marc C. Hochberg, Maarten de Wit, Peter Tugwell, Philip G. Conaghan

APH - Methodology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Objective. To assess the uptake of the OMERACT-OARSI (Outcome Measures in Rheumatology- Osteoarthritis Research Society International) core outcome set (COS) domains in hip and/or knee osteoarthritis (OA) trials. Methods. There were 382 trials of hip and/or knee OA identified from the ClinicalTrial.gov registry from 1997 to 2017. Frequency of COS adoption was assessed by year and per 5-yearly phases. Results. COS adoption decreased from 61% between 1997 and 2001 to 38% between 2012 and 2016. Pain (95%) and physical function (86%) were most consistently adopted. Patient’s global assessment (48%) was the principal missing domain. Conclusion. Limited adoption of the COS domains indicates that further consideration to improve uptake is required.

Original language	English
Pages (from-to)	976-980
Journal	Journal of Rheumatology
Volume	46
Issue number	8
DOIs	https://doi.org/10.3899/jrheum.181066
Publication status	Published - 1 Aug 2019

Access to Document

10.3899/jrheum.181066

Cite this

Smith, T. O., Mansfield, M., Hawker, G. A., Hunter, D. J., March, L. M., Boers, M., Shea, B. J., Christensen, R., Guillemin, F., Terwee, C. B., Williamson, P. R., Roos, E. M., Loeser, R. F., Schnitzer, T. J., Kloppenburg, M., Neogi, T., Ladel, C. H., Kalsi, G., Kaiser, U., ... Conaghan, P. G. (2019). Uptake of the OMERACT-OARSI hip and knee osteoarthritis core outcome set: Review of randomized controlled trials from 1997 to 2017. Journal of Rheumatology, 46(8), 976-980. https://doi.org/10.3899/jrheum.181066

Smith, Toby O. ; Mansfield, Michael ; Hawker, Gillian A. ; Hunter, David J. ; March, Lyn M. ; Boers, Maarten ; Shea, Beverley J. ; Christensen, Robin ; Guillemin, Francis ; Terwee, Caroline B. ; Williamson, Paula R. ; Roos, Ewa M. ; Loeser, Richard F. ; Schnitzer, Thomas J. ; Kloppenburg, Margreet ; Neogi, Tuhina ; Ladel, Christoph H. ; Kalsi, Gurdyal ; Kaiser, Ulrike ; Buttel, Thomas W. ; Ashford, Anne E. ; Mobasheri, Ali ; Arden, Nigel K. ; Tennant, Alan ; Hochberg, Marc C. ; de Wit, Maarten ; Tugwell, Peter ; Conaghan, Philip G. / Uptake of the OMERACT-OARSI hip and knee osteoarthritis core outcome set: Review of randomized controlled trials from 1997 to 2017. In: Journal of Rheumatology. 2019 ; Vol. 46, No. 8. pp. 976-980.

@article{450200f98eba4f3ca22ef7ab925fb2e4,

title = "Uptake of the OMERACT-OARSI hip and knee osteoarthritis core outcome set: Review of randomized controlled trials from 1997 to 2017",

abstract = "Objective. To assess the uptake of the OMERACT-OARSI (Outcome Measures in Rheumatology- Osteoarthritis Research Society International) core outcome set (COS) domains in hip and/or knee osteoarthritis (OA) trials. Methods. There were 382 trials of hip and/or knee OA identified from the ClinicalTrial.gov registry from 1997 to 2017. Frequency of COS adoption was assessed by year and per 5-yearly phases. Results. COS adoption decreased from 61% between 1997 and 2001 to 38% between 2012 and 2016. Pain (95%) and physical function (86%) were most consistently adopted. Patient{\textquoteright}s global assessment (48%) was the principal missing domain. Conclusion. Limited adoption of the COS domains indicates that further consideration to improve uptake is required.",

author = "Smith, {Toby O.} and Michael Mansfield and Hawker, {Gillian A.} and Hunter, {David J.} and March, {Lyn M.} and Maarten Boers and Shea, {Beverley J.} and Robin Christensen and Francis Guillemin and Terwee, {Caroline B.} and Williamson, {Paula R.} and Roos, {Ewa M.} and Loeser, {Richard F.} and Schnitzer, {Thomas J.} and Margreet Kloppenburg and Tuhina Neogi and Ladel, {Christoph H.} and Gurdyal Kalsi and Ulrike Kaiser and Buttel, {Thomas W.} and Ashford, {Anne E.} and Ali Mobasheri and Arden, {Nigel K.} and Alan Tennant and Hochberg, {Marc C.} and {de Wit}, Maarten and Peter Tugwell and Conaghan, {Philip G.}",

year = "2019",

month = aug,

day = "1",

doi = "10.3899/jrheum.181066",

language = "English",

volume = "46",

pages = "976--980",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "8",

}

Smith, TO, Mansfield, M, Hawker, GA, Hunter, DJ, March, LM, Boers, M, Shea, BJ, Christensen, R, Guillemin, F, Terwee, CB, Williamson, PR, Roos, EM, Loeser, RF, Schnitzer, TJ, Kloppenburg, M, Neogi, T, Ladel, CH, Kalsi, G, Kaiser, U, Buttel, TW, Ashford, AE, Mobasheri, A, Arden, NK, Tennant, A, Hochberg, MC, de Wit, M, Tugwell, P & Conaghan, PG 2019, 'Uptake of the OMERACT-OARSI hip and knee osteoarthritis core outcome set: Review of randomized controlled trials from 1997 to 2017', Journal of Rheumatology, vol. 46, no. 8, pp. 976-980. https://doi.org/10.3899/jrheum.181066

Uptake of the OMERACT-OARSI hip and knee osteoarthritis core outcome set: Review of randomized controlled trials from 1997 to 2017. / Smith, Toby O.; Mansfield, Michael; Hawker, Gillian A.; Hunter, David J.; March, Lyn M.; Boers, Maarten; Shea, Beverley J.; Christensen, Robin; Guillemin, Francis; Terwee, Caroline B.; Williamson, Paula R.; Roos, Ewa M.; Loeser, Richard F.; Schnitzer, Thomas J.; Kloppenburg, Margreet; Neogi, Tuhina; Ladel, Christoph H.; Kalsi, Gurdyal; Kaiser, Ulrike; Buttel, Thomas W.; Ashford, Anne E.; Mobasheri, Ali; Arden, Nigel K.; Tennant, Alan; Hochberg, Marc C.; de Wit, Maarten; Tugwell, Peter; Conaghan, Philip G.

In: Journal of Rheumatology, Vol. 46, No. 8, 01.08.2019, p. 976-980.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Uptake of the OMERACT-OARSI hip and knee osteoarthritis core outcome set: Review of randomized controlled trials from 1997 to 2017

AU - Smith, Toby O.

AU - Mansfield, Michael

AU - Hawker, Gillian A.

AU - Hunter, David J.

AU - March, Lyn M.

AU - Boers, Maarten

AU - Shea, Beverley J.

AU - Christensen, Robin

AU - Guillemin, Francis

AU - Terwee, Caroline B.

AU - Williamson, Paula R.

AU - Roos, Ewa M.

AU - Loeser, Richard F.

AU - Schnitzer, Thomas J.

AU - Kloppenburg, Margreet

AU - Neogi, Tuhina

AU - Ladel, Christoph H.

AU - Kalsi, Gurdyal

AU - Kaiser, Ulrike

AU - Buttel, Thomas W.

AU - Ashford, Anne E.

AU - Mobasheri, Ali

AU - Arden, Nigel K.

AU - Tennant, Alan

AU - Hochberg, Marc C.

AU - de Wit, Maarten

AU - Tugwell, Peter

AU - Conaghan, Philip G.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Objective. To assess the uptake of the OMERACT-OARSI (Outcome Measures in Rheumatology- Osteoarthritis Research Society International) core outcome set (COS) domains in hip and/or knee osteoarthritis (OA) trials. Methods. There were 382 trials of hip and/or knee OA identified from the ClinicalTrial.gov registry from 1997 to 2017. Frequency of COS adoption was assessed by year and per 5-yearly phases. Results. COS adoption decreased from 61% between 1997 and 2001 to 38% between 2012 and 2016. Pain (95%) and physical function (86%) were most consistently adopted. Patient’s global assessment (48%) was the principal missing domain. Conclusion. Limited adoption of the COS domains indicates that further consideration to improve uptake is required.

AB - Objective. To assess the uptake of the OMERACT-OARSI (Outcome Measures in Rheumatology- Osteoarthritis Research Society International) core outcome set (COS) domains in hip and/or knee osteoarthritis (OA) trials. Methods. There were 382 trials of hip and/or knee OA identified from the ClinicalTrial.gov registry from 1997 to 2017. Frequency of COS adoption was assessed by year and per 5-yearly phases. Results. COS adoption decreased from 61% between 1997 and 2001 to 38% between 2012 and 2016. Pain (95%) and physical function (86%) were most consistently adopted. Patient’s global assessment (48%) was the principal missing domain. Conclusion. Limited adoption of the COS domains indicates that further consideration to improve uptake is required.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85069580957&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30824657

U2 - 10.3899/jrheum.181066

DO - 10.3899/jrheum.181066

M3 - Article

C2 - 30824657

VL - 46

SP - 976

EP - 980

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 8

ER -